Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies

Affiliations

¹ Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. Electronic address: fabio.piscaglia@unibo.it.
² Department of Medical and Surgical Sciences, University of Bologna, Italy.

Comment

Fabio Piscaglia et al. Dig Liver Dis. 2022 Nov.

. 2022 Nov;54(11):1561-1562.

doi: 10.1016/j.dld.2022.08.032. Epub 2022 Sep 18.

¹ Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. Electronic address: fabio.piscaglia@unibo.it.
² Department of Medical and Surgical Sciences, University of Bologna, Italy.

No abstract available

Comment on

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Stefanini B, et al. Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003. Epub 2022 Jul 27. Dig Liver Dis. 2022. PMID: 35906166